Evusheld shows promise for protecting against Covid in vulnerable groups, highlighting its role when vaccines are ineffective.
Evusheld is a combination of two long-acting antibodies (tixagevimab and cilgavimab). It's a drug designed to protect clinically vulnerable people against Covid in cases where vaccines don't work.
No takes yet. Share an insight, caveat, or question.
Martin Paul Eve (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: